Trending NewsTrending NewsNASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $1.92 0.00 (0.00%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$1.98 +0.06 (+2.86%) As of 07/31/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Karyopharm Therapeutics Stock (NASDAQ:KPTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KPTI alerts:Sign Up Key Stats Today's Range$1.80▼$2.4350-Day Range$1.92▼$10.6752-Week Range$1.80▼$10.99Volume22.16 million shsAverage Volume1.88 million shsMarket Capitalization$43.51 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways. The company conducts clinical trials both domestically and internationally, working with regulatory agencies in the United States and Europe. Through strategic collaborations, Karyopharm seeks to expand the therapeutic reach of its SINE technology into other areas of oncology and potentially neurodegenerative diseases. Karyopharm is led by Michael Kauffman, M.D., President and Chief Executive Officer, who co-founded the company and has guided its transition from preclinical research to commercial-stage operations. Under his leadership, Karyopharm has forged partnerships with global pharmaceutical firms to advance pipeline candidates and ensure broader patient access. The company maintains a scientific advisory board composed of experts in cancer biology, translational medicine and drug development.AI Generated. May Contain Errors. Read More Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreKPTI MarketRank™: Karyopharm Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 677th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKaryopharm Therapeutics has a consensus price target of $11.50, representing about 499.0% upside from its current price of $1.92.Amount of Analyst CoverageKaryopharm Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to decrease in the coming year, from ($3.24) to ($4.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.33% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 17.13, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 4.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.22 News SentimentKaryopharm Therapeutics has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Karyopharm Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.68% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Stock News HeadlinesPiper Sandler Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $7.003 hours ago | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Cut to "Neutral" at Robert W. Baird3 hours ago | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 3 at 1:00 AM | Banyan Hill Publishing (Ad)Karyopharm Therapeutics' (KPTI) Neutral Rating Reiterated at HC Wainwright4 hours ago | americanbankingnews.comWhy is KPTI stock down 69% after-hours today?August 1 at 2:13 PM | msn.comHead-To-Head Analysis: XTL Biopharmaceuticals (NASDAQ:XTLB) vs. Karyopharm Therapeutics (NASDAQ:KPTI)August 1 at 1:59 AM | americanbankingnews.comKaryopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial CancerJuly 31 at 6:54 PM | finanznachrichten.deKaryopharm stock (KPTI) crashes after hours: Here's what's driving the moveJuly 31 at 8:52 AM | msn.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $7.36 at the beginning of the year. Since then, KPTI shares have decreased by 73.9% and is now trading at $1.92. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.21. The firm earned $35.07 million during the quarter, compared to analyst estimates of $31.40 million. Read the conference call transcript. When did Karyopharm Therapeutics' stock split? Shares of Karyopharm Therapeutics reverse split on Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Karyopharm Therapeutics IPO? Karyopharm Therapeutics (KPTI) raised $102 million in an initial public offering on Wednesday, November 6th 2013. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS). Company Calendar Last Earnings5/14/2026Today8/03/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 As of 3 days ago, KPTI's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees380Year Founded2008Price Target and Rating Average Price Target for Karyopharm Therapeutics$11.50 High Price Target$28.00 Low Price Target$3.00 Potential Upside/Downside+499.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($15.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.04 million Net Margins-129.02% Pretax Margin-129.01% Return on EquityN/A Return on Assets-120.29% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio1.05 Sales & Book Value Annual Sales$146.07 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($16.00) per share Price / Book-0.12Miscellaneous Outstanding Shares22,660,000Free Float22,282,000Market Cap$43.51 million OptionableOptionable Beta0.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:KPTI) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
